Mirati Therapeutics Inc (MRTX) Stake Raised by Amundi Pioneer Asset Management Inc.

Amundi Pioneer Asset Management Inc. raised its position in Mirati Therapeutics Inc (NASDAQ:MRTX) by 44.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 268,100 shares of the biotechnology company’s stock after purchasing an additional 82,900 shares during the period. Amundi Pioneer Asset Management Inc. owned 0.78% of Mirati Therapeutics worth $11,373,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the business. United Services Automobile Association raised its position in shares of Mirati Therapeutics by 2.5% during the 4th quarter. United Services Automobile Association now owns 7,222 shares of the biotechnology company’s stock valued at $306,000 after buying an additional 173 shares in the last quarter. Meeder Asset Management Inc. raised its position in shares of Mirati Therapeutics by 12.9% during the 4th quarter. Meeder Asset Management Inc. now owns 2,087 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 239 shares in the last quarter. TD Asset Management Inc. raised its position in shares of Mirati Therapeutics by 1.9% during the 4th quarter. TD Asset Management Inc. now owns 15,800 shares of the biotechnology company’s stock valued at $670,000 after buying an additional 300 shares in the last quarter. Northern Trust Corp raised its position in shares of Mirati Therapeutics by 0.5% during the 4th quarter. Northern Trust Corp now owns 274,475 shares of the biotechnology company’s stock valued at $11,643,000 after buying an additional 1,444 shares in the last quarter. Finally, American International Group Inc. raised its position in shares of Mirati Therapeutics by 13.4% during the 3rd quarter. American International Group Inc. now owns 13,381 shares of the biotechnology company’s stock valued at $630,000 after buying an additional 1,582 shares in the last quarter.

Shares of MRTX traded up $1.04 during trading hours on Friday, reaching $63.27. 434,499 shares of the company traded hands, compared to its average volume of 510,018. The firm has a market capitalization of $2.23 billion, a price-to-earnings ratio of -19.83 and a beta of 2.10. Mirati Therapeutics Inc has a 12 month low of $26.00 and a 12 month high of $80.00.

In related news, Director Craig A. Johnson sold 17,000 shares of the business’s stock in a transaction dated Tuesday, January 29th. The shares were sold at an average price of $61.46, for a total transaction of $1,044,820.00. Following the sale, the director now owns 7,000 shares of the company’s stock, valued at $430,220. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Venbio Select Advisor Llc sold 686,820 shares of the business’s stock in a transaction dated Wednesday, February 20th. The stock was sold at an average price of $73.00, for a total transaction of $50,137,860.00. The disclosure for this sale can be found here. Insiders have sold a total of 1,399,911 shares of company stock worth $100,817,770 in the last ninety days. Insiders own 4.86% of the company’s stock.

Several analysts have recently weighed in on MRTX shares. Oppenheimer raised their price objective on shares of Mirati Therapeutics from $57.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, January 16th. BidaskClub upgraded shares of Mirati Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 5th. HC Wainwright reiterated a “buy” rating on shares of Mirati Therapeutics in a research report on Friday, February 15th. Piper Jaffray Companies initiated coverage on shares of Mirati Therapeutics in a research report on Friday, February 15th. They issued an “overweight” rating and a $85.00 target price on the stock. Finally, Cantor Fitzgerald began coverage on shares of Mirati Therapeutics in a research report on Monday, March 4th. They issued a “neutral” rating and a $66.00 target price on the stock. Five research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $69.08.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/amundi-pioneer-asset-management-inc-grows-stake-in-mirati-therapeutics-inc-mrtx.html.

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers.

See Also: Conference Calls

Institutional Ownership by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.